CZEN-002 demonstrated anti-infective and anti-inflammatory properties, with 88.2% of subjects showing efficacy in potassium hydroxide tests and mycological cultures. The treatment was well-tolerated with no significant changes from baseline vital signs.
The study, published in Pharmacological Reviews, reveals that activation of certain melanocortin receptors can modulate the inflammatory process, reducing major molecules involved. This discovery has implications for treating localized and systemic inflammatory disorders, including organ transplantation and chronic inflammatory diseases.
Studies found that patients with acute brain injury had lower levels of anti-inflammatory molecule a-MSH, which remained low over four days after injury. This impairment may have detrimental consequences for brain injury treatment.
Researchers at Zengen developed a 'super peptide' that kills Candida albicans with high candidacidal activity, outperforming existing antimicrobial peptides. The discovery may help understand the unique mechanism of action of a-MSH peptides and unlock new treatments for fungal infections.
Researchers at Zengen discovered that synthetic alpha-Melanocyte-Stimulating Hormone (a-MSH) has an anti-inflammatory effect in celiac mucosa, which may control the inflammatory response and limit epithelial damage. This finding could lead to a medical treatment for Celiac disease, currently managed only with a strict gluten-free diet.